Posted by Michael Wonder on 30 Jul 2024
HLS announces reimbursement for Vascepa under Alberta's Provincial Drug Plan
29 July 2024 - With the addition of Alberta's public plan, Vascepa will be available to more than 90% of Canadians who are eligible and covered by a public or private plan.
HLS Therapeutics announces that it has entered into a Product Listing Agreement with the province of Alberta, for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with Alberta Health is effective 1 August 2024.
